Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-methoxy-2-aminoindane + palmitoylethanolamide
- Development stage
- Unknown
- Lead developer
- Clearmind Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination drug consists of 5-methoxy-2-aminoindane (MEAI), a synthetic aminoindane derivative, and palmitoylethanolamide (PEA), an endogenous fatty acid amide. MEAI acts primarily as a selective serotonin releasing agent (SSRA) and is being investigated for its potential to reduce alcohol consumption by mimicking the pleasurable effects of alcohol without the associated toxicity or impairment. PEA is included in the formulation to potentially enhance the safety profile and provide anti-inflammatory and neuroprotective benefits via its action as a PPAR-alpha agonist. The combination is primarily being developed by Clearmind Medicine for the treatment of Alcohol Use Disorder (AUD) and other addictive behaviors, such as binge eating.
- Other names
- MEAI + PEA5-MeO-AI + PEA
02
Targets
HTR2A (5-hydroxytryptamine receptor 2A)ADRA2B (α2B)HTR2B (5-Hydroxytryptamine Receptor 2B)TRPV1 (Transient receptor potential cation channel subfamily V member 1)DAT (Dopamine plasma membrane transport protein)PPARA (Peroxisome proliferator-activated receptor alpha)ADRA2A (α2A)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)ADRA2C (α2C)GPR55 (G protein-coupled receptor 55)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on 5-methoxy-2-aminoindane + palmitoylethanolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-methoxy-2-aminoindane + palmitoylethanolamide.